What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to furnish financial information from Pfizer's previous Form 10-Q in XBRL format as part of the SEC's voluntary XBRL pilot program. This allows for testing of the XBRL reporting technology.

Should I use the financial data in this 8-K to make investment decisions?

No, investors are strongly advised not to rely on the financial information provided in this 8-K filing for investment decisions. The XBRL-formatted data is unaudited and for pilot program testing purposes only. Investors should refer to the official, audited financial statements previously filed with the SEC.

What specific financial statements are included in the XBRL format?

The XBRL-formatted exhibits include condensed consolidated statements of income for the three and six months ended July 2, 2006, and July 3, 2005; condensed consolidated balance sheets at July 2, 2006, and December 31, 2005; and condensed consolidated statements of cash flows for the six months ended July 2, 2006, and July 3, 2005.

Does filing this XBRL data make Pfizer liable for its accuracy under securities law?

No, according to Rule 402 of Regulation S-T, the information furnished in this 8-K, including the XBRL data, is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. Therefore, it does not subject Pfizer to the liabilities of that section.

PFE 8-K SEC Disclosure — Nov 30, 2006

Summary

Pfizer Inc. filed this Current Report on Form 8-K on November 30, 2006, to furnish documents formatted in XBRL (eXtensible Business Reporting Language). These XBRL documents contain financial information from Pfizer's Quarterly Report on Form 10-Q for the quarter ended July 2, 2006, which was originally filed on August 11, 2006. The included financial data comprises condensed consolidated statements of income, balance sheets, and cash flows for specific periods in 2006 and 2005. It is crucial for investors to understand that this 8-K filing is part of the SEC's voluntary XBRL pilot program. The XBRL-formatted financial information provided herein is unaudited and should not be considered the official financial statements. Investors are strongly advised to rely on the officially filed versions of the documents and not to make investment decisions based on the information presented in this 8-K or its exhibits.

Key Highlights

1Pfizer is participating in the SEC's voluntary XBRL pilot program to test XBRL technology.
2The filing furnishes XBRL-formatted financial data from Pfizer's Form 10-Q for the quarter ended July 2, 2006.
3The XBRL data includes condensed consolidated statements of income, balance sheets, and cash flows.
4The XBRL financial information is explicitly stated as unaudited.
5Investors are cautioned not to rely on this XBRL data for investment decisions; official filings should be used.
6This filing does not create new liabilities under Section 18 of the Exchange Act for the furnished XBRL data.

PFIZER INC 8-K Report, Corporate Update (Nov 30, 2006)

Summary

Key Highlights

Frequently Asked Questions